Real-World Treatment Patterns in Patients With Metastatic Castration-Resistant Prostate Cancer in Greece: The PROSPECT Study

IF 2.3 3区 医学 Q3 ONCOLOGY
M. Liontos , E. Bournakis , A. Bournakis , E. Kostouros , V. Zolota , A.P. Papatheodoridi , K. Karalis , A. Kyriazoglou , R. Zakopoulou , E. Vasili , A. Tzovaras , I. Dimitriadis , G. Emmanouil , D. Mauri , C. Christodoulou , M. Tsiatas , F. Zagouri , A. Bamias
{"title":"Real-World Treatment Patterns in Patients With Metastatic Castration-Resistant Prostate Cancer in Greece: The PROSPECT Study","authors":"M. Liontos ,&nbsp;E. Bournakis ,&nbsp;A. Bournakis ,&nbsp;E. Kostouros ,&nbsp;V. Zolota ,&nbsp;A.P. Papatheodoridi ,&nbsp;K. Karalis ,&nbsp;A. Kyriazoglou ,&nbsp;R. Zakopoulou ,&nbsp;E. Vasili ,&nbsp;A. Tzovaras ,&nbsp;I. Dimitriadis ,&nbsp;G. Emmanouil ,&nbsp;D. Mauri ,&nbsp;C. Christodoulou ,&nbsp;M. Tsiatas ,&nbsp;F. Zagouri ,&nbsp;A. Bamias","doi":"10.1016/j.clgc.2024.102170","DOIUrl":null,"url":null,"abstract":"<div><h3>Introduction</h3><p>Real-world data on management of metastatic castration resistant prostate cancer (mCRPC) with novel therapies is sparse. The aim of this study was to capture real-world management strategies in patients with mCRPC who initiated first line (1L) systemic therapy with chemotherapy or novel hormonal agents (NHAs) in Greece and describe the therapeutic sequencing strategy among patients who advanced to 2L and 3L treatment.</p></div><div><h3>Patients and Methods</h3><p>In this noninterventional, multicentre, retrospective study (PROSPECT), a medical chart review of 149 patients with mCRPC who initiated 1L systemic therapy with chemotherapy or NHAs in 7 major anticancer hospital clinics, from public, academic, and private sectors in Greece was conducted. All endpoints were descriptively analysed. Kaplan–Meier was used for time-to-event outcomes.</p></div><div><h3>Results</h3><p>At 1L (N = 149), most (78.5%) patients received NHAs; enzalutamide (52.3%), and abiraterone (26.2%). At 2L (N = 68), most (72.1%) patients received chemotherapy, most frequently docetaxel (50.0% of all patients). At 3L (N = 32), 56.3% and 31.3% of patients received chemotherapy and NHAs, respectively. Regarding treatment sequencing from 1L→2L (N = 68), most patients (55.9%) advanced from NHA→chemotherapy. Regarding treatment sequencing from 1L→2L→3L (N = 32), 34.4% advanced from NHAs→chemotherapy→chemotherapy and 31.3% from NHAs→chemotherapy→NHA. Estimated median times spent on treatment at 1L, 2L, and 3L were 9.8, 4.4, and 3.7 months, respectively.</p></div><div><h3>Conclusion</h3><p>Most patients were treated with 1L NHAs, in accordance to established guidelines (which suggest both NHA and chemo as preferred 1st line options). There appeared to be a longer time on treatment of NHAs at 1L than chemotherapy, suggesting an unmet need for treatment optimisation/recommendations for 2L and 3L treatment in mCRPC.</p></div>","PeriodicalId":10380,"journal":{"name":"Clinical genitourinary cancer","volume":"22 6","pages":"Article 102170"},"PeriodicalIF":2.3000,"publicationDate":"2024-07-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical genitourinary cancer","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1558767324001411","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction

Real-world data on management of metastatic castration resistant prostate cancer (mCRPC) with novel therapies is sparse. The aim of this study was to capture real-world management strategies in patients with mCRPC who initiated first line (1L) systemic therapy with chemotherapy or novel hormonal agents (NHAs) in Greece and describe the therapeutic sequencing strategy among patients who advanced to 2L and 3L treatment.

Patients and Methods

In this noninterventional, multicentre, retrospective study (PROSPECT), a medical chart review of 149 patients with mCRPC who initiated 1L systemic therapy with chemotherapy or NHAs in 7 major anticancer hospital clinics, from public, academic, and private sectors in Greece was conducted. All endpoints were descriptively analysed. Kaplan–Meier was used for time-to-event outcomes.

Results

At 1L (N = 149), most (78.5%) patients received NHAs; enzalutamide (52.3%), and abiraterone (26.2%). At 2L (N = 68), most (72.1%) patients received chemotherapy, most frequently docetaxel (50.0% of all patients). At 3L (N = 32), 56.3% and 31.3% of patients received chemotherapy and NHAs, respectively. Regarding treatment sequencing from 1L→2L (N = 68), most patients (55.9%) advanced from NHA→chemotherapy. Regarding treatment sequencing from 1L→2L→3L (N = 32), 34.4% advanced from NHAs→chemotherapy→chemotherapy and 31.3% from NHAs→chemotherapy→NHA. Estimated median times spent on treatment at 1L, 2L, and 3L were 9.8, 4.4, and 3.7 months, respectively.

Conclusion

Most patients were treated with 1L NHAs, in accordance to established guidelines (which suggest both NHA and chemo as preferred 1st line options). There appeared to be a longer time on treatment of NHAs at 1L than chemotherapy, suggesting an unmet need for treatment optimisation/recommendations for 2L and 3L treatment in mCRPC.

希腊转移性抗性前列腺癌患者的实际治疗模式:PROSPECT 研究
导言:有关采用新型疗法治疗转移性去势抵抗性前列腺癌(mCRPC)的真实世界数据非常稀少。本研究旨在了解在希腊开始接受化疗或新型激素类药物(NHA)一线(1L)系统治疗的mCRPC患者的实际管理策略,并描述进展到2L和3L治疗的患者的治疗排序策略。患者和方法在这项非介入、多中心、回顾性研究(PROSPECT)中,对希腊公立、学术和私立 7 家主要抗癌医院诊所中接受化疗或 NHAs 1L 全身治疗的 149 名 mCRPC 患者进行了病历回顾。对所有终点进行了描述性分析。结果1L时(149例),大多数(78.5%)患者接受了NHAs治疗;恩扎鲁胺(52.3%)和阿比特龙(26.2%)。在 2L(68 人)阶段,大多数(72.1%)患者接受化疗,最常见的是多西他赛(占所有患者的 50.0%)。在 3L(32 人)阶段,分别有 56.3% 和 31.3% 的患者接受化疗和 NHAs 治疗。关于从1L→2L(68例)的治疗顺序,大多数患者(55.9%)从NHA→化疗。至于从 1L→2L→3L(N = 32)的治疗顺序,34.4% 的患者从 NHAs→chemotherapy→chemotherapy 中进展,31.3% 的患者从 NHAs→chemotherapy→NHA 中进展。1L 、2L 和 3L 治疗的估计中位时间分别为 9.8 个月、4.4 个月和 3.7 个月。结论根据既定指南(指南建议 NHA 和化疗都是首选的一线方案),大多数患者都接受了 1L NHA 治疗。与化疗相比,1L NHA的治疗时间似乎更长,这表明mCRPC患者对2L和3L治疗的优化/建议需求尚未得到满足。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Clinical genitourinary cancer
Clinical genitourinary cancer 医学-泌尿学与肾脏学
CiteScore
5.20
自引率
6.20%
发文量
201
审稿时长
54 days
期刊介绍: Clinical Genitourinary Cancer is a peer-reviewed journal that publishes original articles describing various aspects of clinical and translational research in genitourinary cancers. Clinical Genitourinary Cancer is devoted to articles on detection, diagnosis, prevention, and treatment of genitourinary cancers. The main emphasis is on recent scientific developments in all areas related to genitourinary malignancies. Specific areas of interest include clinical research and mechanistic approaches; drug sensitivity and resistance; gene and antisense therapy; pathology, markers, and prognostic indicators; chemoprevention strategies; multimodality therapy; and integration of various approaches.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信